Product Highlight - LUMIRIX

Reimagine Vitiligo Treatment with Lumirix^®

• The first approved topical treatment for non-segmental vitiligo in adults & adolescents ≥12 years of age^1,2

• Lumirix^® improves vitiligo scores and repigmentation^3,4

• About 3 in 5 patients who continued the application of Lumirix^® maintained F-VASI75 at Week 104 and 1 in 2 patients maintained F-VASI90.³

• Lumirix^® is well-tolerated⁴

(F-VASI, facial vitiligo area scoring index)

References:
1. Lumirix^® HK Package Insert 2024.
2. C.Kang, Drugs 2024:84:579-586.
3. Rosmarin D, et al. Presented at the European Academy of Dermatology and Venereology (EADV) Congress; September 25-28 2024; Amsterdam, Netherlands.
4. Rosmarin D, et al. 'Two Phase 3, Randomized, Controlled Trials of Rxolitinib Cream for Vitiligo', The New England Journal of MEDICINE 2022;387;1445-55.